{"name":"Bio-Path Holdings, Inc.","slug":"bio-path-holdings-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":7295000,"netIncome":-9894000,"cash":3883000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BP1001 plus decitabine","genericName":"BP1001 plus decitabine","slug":"bp1001-plus-decitabine","indication":"Acute myeloid leukemia (AML)","status":"phase_2"}]}],"pipeline":[{"name":"BP1001 plus decitabine","genericName":"BP1001 plus decitabine","slug":"bp1001-plus-decitabine","phase":"phase_2","mechanism":"Decitabine is a hypomethylating agent that targets DNA methyltransferase 1 (DNMT1)","indications":["Acute myeloid leukemia (AML)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9OWndXeDhiTW9jS1dCeU5QdDNQeWFxcFc2YnZ3VUhQLU9pV3JkdEpNQW90V0RYZnh5N2x6dGI0Z0ZacWtZYS1YSU5rSm1TdWpZTUxBOUlFTWRMQVdtLUZ4TQ?oc=5","date":"2026-03-27","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRXpPYU1Zd2xLTlFSNTJQa212d1NNQzY0dGxjNXZyN2JteUNnem5JRHR6Z3BkeFZNNTNyLXlOQktpbHhDWl9yM0JnQnAwcXlNZjlmTFdWc3psWUNsZDRyOXNuXy1MU3NmaTgzUHJ1bWNIY0hYOTloNzVQRU9xVlNSc1V3bWhoYUxCVWFreS1hX3NBTkowOUE5eGM3UFFMUXc?oc=5","date":"2026-03-25","type":"pipeline","source":"Stock Titan","summary":"[1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan","headline":"[1-A] BIO-PATH HOLDINGS, INC. SEC Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNV2JVc1E3SDF2WkZNQmpLODd3Ul9IU1loV1pyb2N6M0RaTjBvQ2hLWlN1cVlISVBJUkpNamdMTXUxNGtGbnNjZm10MDhaZkpqdDdmOTRUQ0Zydi1qUjNDaGJtLTB5OXp0ai1DNE5QR1dZRWhodHF5QnhWX2dwQkh0aDFDZFFpSlVwdGZrMTV6Z09ENkxQZlRMaVVadDJ1eWlBaXE5TUZ5cUdhNlpYTXg3eXVfS2RVTUNrVmJuZ2IxT3JLc190b2dYY1FpOEQ?oc=5","date":"2026-03-20","type":"regulatory","source":"Investing.com","summary":"Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com","headline":"Bio-Path Holdings approves Wyoming move and creates new preferred stock class","sentiment":"positive"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQNHZTNmtYT25FWW9jalV6OGhOMUpKZTdrVGFLQ2xsRjRuZHZ1NklFUzY1Q0ZPNVZMS1VWUGFKbWp5RGZaY3pxLWFfZ1dyV2c4ZDZWTW04SnJDWHlJZHFmM2JrdjM0aHN4RWVvYXJ1WVhJZktqaWdWOS1IU3N5NmllOHNGUEw2eVZQVGZybTdSTjktdkZzTkdBd2tqNDRaSXVqMTV3ZmhIWHllY2RncWNj?oc=5","date":"2026-03-19","type":"pipeline","source":"Stock Titan","summary":"[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan","headline":"[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNb0NDcXVWbnY2SWVnZzZ3bmR4ejdxajJmNFpxSXJJaFgxOFVzaXhqUWVvUWRQMTRRclRLd1BmZkMzbHBhWXZZSHg3RVlSV3F1TDZKTUpqVjhvTVNtMHJqVU1VczZhVEpFb0VNb0RFTkxDMF92T0t0TG1vY0ZaeWxNU0p2ZjAyVjFoUGJsN3Rqa3VGc0RjN1hBOGJFMUNrMFZ3OGk5SGR1TlgzbDVSYi1MVzdrTndGd3M4cHFoV2lIX0QxV25DdVRmTnFOVFo4MzEwdmFoNmhwMG5QVklPNzRCXw?oc=5","date":"2026-03-18","type":"earnings","source":"marketscreener.com","summary":"Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com","headline":"Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"pipeline","source":"simplywall.st","summary":"Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - simplywall.st","headline":"Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOdkJBM0w4TUUxY2d1Sm1pTWtIWC1jeTc5M1l1Um9PejR0ZTBGNUV1Y0drM1Vzbl92RTM1QnJiVFJiZEpBTjBVWDhIaTVDamZvNTE3UDZVR1Q2b21iQTkxQ3l1VU0xX2swSzR4TXlFOUVkaUpFUlpGSHZzU2sySEN3Rml4SWpvdVh3ckJZdGk0U1lVaXg1U3FJ?oc=5","date":"2025-12-22","type":"pipeline","source":"BioWorld News","summary":"Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld News","headline":"Mondego Bio selects ZE00-0388 as clinical candidate","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"date":"2025-08-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-08-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"},{"value":37000,"period":"2017-12-31"},{"value":37000,"period":"2017-12-31"},{"value":13000,"period":"2016-12-31"},{"value":13000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7295000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-9894000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":3883000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}